---
title: "Perioperative ivonescimab ± chemotherapy Yields High MPR in Resectable NSCLC (Phase 2)"
id: "nature-1-perioperative-ivonescimab-with-or-without-chemotherapy-in-resectable-non-small"
canonical_url: "https://medichelpline.com/clinical-feed/nature-1-perioperative-ivonescimab-with-or-without-chemotherapy-in-resectable-non-small"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04745-4"
published_at: "2026-11-04T11:11:07.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Perioperative ivonescimab ± chemotherapy Yields High MPR in Resectable NSCLC (Phase 2)
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-1-perioperative-ivonescimab-with-or-without-chemotherapy-in-resectable-non-small
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04745-4)
- **Published At:** 2026-11-04T11:11:07.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- This nonrandomized, noncomparative phase 2 trial tested perioperative **ivonescimab** as neoadjuvant monotherapy (cohort 1) or given with chemotherapy (cohort 2), followed by surgery and adjuvant ivonescimab. - The primary endpoint was major pathological response (**MPR**); cohort 2 met the prespecified threshold versus a historical control rate. - Cohort 2 achieved an **MPR** rate of 70.1% (47/67); investigators reported the lower bound of the 80% two-sided CI exceeded the historical 41% rate. - Cohort 1 showed an **MPR** of 60.0% (6/10); confidence intervals reported by the authors were wide, reflecting small sample size. - Among MPR responders, residual viable tumor (RVT) ≤5% occurred in 5/6 (83.3%) in cohort 1 and 46/47 (97.9%) in cohort 2. - Grade ≥3 treatment-related adverse events (AEs) occurred in 36.4% (4/11) in cohort 1 and 30.4% (24/79) in cohort 2; no grade ≥3 hemorrhage or treatment-related deaths were reported. - Treatment-related surgery delay was recorded in one patient (1.3%). - Surgery-related AEs judged related to **ivonescimab** occurred in ~10% of patients in both cohorts with no grade ≥3 events. - The trial is registered as NCT05247684. - The source did not report additional randomized comparator data, long-term survival outcomes, or detailed dosing and schedule specifics beyond the neoadjuvant/ adjuvant framework described.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41591-026-04745-4#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Medicine](https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg) ](https://www.nature.com/nm) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-026-04745-4) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nm/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nm/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nm/news-and-comment) * [ Podcasts ](https://www.nature.com/nm/podcast) * [ Current issue ](https://www.nature.com/nm/current-issue) * [ Collections ](https://www.nature.com/nm/collections) * [Follow us on Facebook ](https://www.facebook.com/Nature-Medicine-193691346949/) * [Follow us on X ](https://twitter.com/naturemedicine) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nm/aims) * [ Journal Information ](https://www.nature.com/nm/journal-information) * [ Editors ](https://www.nature.com/nm/editors) * [ Journal Metrics ](https://www.nature.com/nm/journal-impact) * [ Research Cross-Journal Editorial Team ](https://www.nature.com/nm/research-cross-journal-editorial-team) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nm/reviews-cross-journal-editorial-team) * [ Statistical Advisory Panel ](https://www.nature.com/nm/statistics-advisory-panel) * [ Our publishing models ](https://www.nature.com/nm/our-publishing-models) * [ Editorial Values Statement ](https://www.nature.com/nm/editorial-values-statement) * [ Editorial Policies ](https://www.nature.com/nm/editorial-policies) * [ Content Types ](https://www.nature.com/nm/content) * [ Web Feeds ](https://www.nature.com/nm/web-feeds) * [ Contact ](https://www.nature.com/nm/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ Submission Guidelines ](https://www.nature.com/nm/submission-guidelines) * [ For Reviewers ](https://www.nature.com/nm/for-reviewers) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/nm/open-access-funding) * [Submit manuscript ](https://mts-nmed.nature.com/cgi-bin/main.plex) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) 1. [nature](https://www.nature.com/) 2. [nature medicine](https://www.nature.com/nm) 3. [articles](https://www.nature.com/nm/articles?type=article) 4. article Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial [ Download PDF ](https://www.nature.com/articles/s41591-026-04745-4.pdf) [ Download PDF ](https://www.nature.com/articles/s41591-026-04745-4.pdf) * Article * [Open access](https://www.springernature.com/gp/open-science/about/the-fundamentals-of-open-access-and-open-research) * Published: 04 November 2026 # Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial * [Xiaoliang Zhao](https://www.nature.com/articles/s41591-026-04745-4#auth-Xiaoliang-Zhao-Aff1) [ORCID: orcid.org/0009-0000-7207-6555](https://orcid.org/0009-0000-7207-6555)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1) [na1](https://www.nature.com/articles/s41591-026-04745-4#na1), * [Bin Zhang](https://www.nature.com/articles/s41591-026-04745-4#auth-Bin-Zhang-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1) [na1](https://www.nature.com/articles/s41591-026-04745-4#na1), * [Chenguang Li](https://www.nature.com/articles/s41591-026-04745-4#auth-Chenguang-Li-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1) [na1](https://www.nature.com/articles/s41591-026-04745-4#na1), * [Lianmin Zhang](https://www.nature.com/articles/s41591-026-04745-4#auth-Lianmin-Zhang-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Meng Wang](https://www.nature.com/articles/s41591-026-04745-4#auth-Meng-Wang-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Ziqiang Tian](https://www.nature.com/articles/s41591-026-04745-4#auth-Ziqiang-Tian-Aff2)[2](https://www.nature.com/articles/s41591-026-04745-4#Aff2), * [Shengguang Wang](https://www.nature.com/articles/s41591-026-04745-4#auth-Shengguang-Wang-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Qiang Zhang](https://www.nature.com/articles/s41591-026-04745-4#auth-Qiang-Zhang-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Huilai Lv](https://www.nature.com/articles/s41591-026-04745-4#auth-Huilai-Lv-Aff2)[2](https://www.nature.com/articles/s41591-026-04745-4#Aff2), * [Chong Pang](https://www.nature.com/articles/s41591-026-04745-4#auth-Chong-Pang-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Shiwang Wen](https://www.nature.com/articles/s41591-026-04745-4#auth-Shiwang-Wen-Aff2)[2](https://www.nature.com/articles/s41591-026-04745-4#Aff2), * [Xiaofei Wang](https://www.nature.com/articles/s41591-026-04745-4#auth-Xiaofei-Wang-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Wei Wei](https://www.nature.com/articles/s41591-026-04745-4#auth-Wei-Wei-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Yu Zhang](https://www.nature.com/articles/s41591-026-04745-4#auth-Yu-Zhang-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Wuhao Huang](https://www.nature.com/articles/s41591-026-04745-4#auth-Wuhao-Huang-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Jianquan Zhu](https://www.nature.com/articles/s41591-026-04745-4#auth-Jianquan-Zhu-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Yue Li](https://www.nature.com/articles/s41591-026-04745-4#auth-Yue-Li-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Chen Chen](https://www.nature.com/articles/s41591-026-04745-4#auth-Chen-Chen-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Yao Tang](https://www.nature.com/articles/s41591-026-04745-4#auth-Yao-Tang-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Bin Jia](https://www.nature.com/articles/s41591-026-04745-4#auth-Bin-Jia-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Hua Zhang](https://www.nature.com/articles/s41591-026-04745-4#auth-Hua-Zhang-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Hui Chen](https://www.nature.com/articles/s41591-026-04745-4#auth-Hui-Chen-Aff1)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Sha Wang](https://www.nature.com/articles/s41591-026-04745-4#auth-Sha-Wang-Aff3)[3](https://www.nature.com/articles/s41591-026-04745-4#Aff3), * [Jiangyan Zhang](https://www.nature.com/articles/s41591-026-04745-4#auth-Jiangyan-Zhang-Aff3) [ORCID: orcid.org/0009-0006-3829-603X](https://orcid.org/0009-0006-3829-603X)[3](https://www.nature.com/articles/s41591-026-04745-4#Aff3), * [Wenting Li](https://www.nature.com/articles/s41591-026-04745-4#auth-Wenting-Li-Aff4)[4](https://www.nature.com/articles/s41591-026-04745-4#Aff4), * [Zhongmin Maxwell Wang](https://www.nature.com/articles/s41591-026-04745-4#auth-Zhongmin_Maxwell-Wang-Aff4) [ORCID: orcid.org/0000-0002-1683-5147](https://orcid.org/0000-0002-1683-5147)[4](https://www.nature.com/articles/s41591-026-04745-4#Aff4), * [Baiyong Li](https://www.nature.com/articles/s41591-026-04745-4#auth-Baiyong-Li-Aff4)[4](https://www.nature.com/articles/s41591-026-04745-4#Aff4), * [Michelle Xia](https://www.nature.com/articles/s41591-026-04745-4#auth-Michelle-Xia-Aff4)[4](https://www.nature.com/articles/s41591-026-04745-4#Aff4), * [Zhenfa Zhang](https://www.nature.com/articles/s41591-026-04745-4#auth-Zhenfa-Zhang-Aff1) [ORCID: orcid.org/0000-0002-9627-2590](https://orcid.org/0000-0002-9627-2590)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1), * [Dongsheng Yue](https://www.nature.com/articles/s41591-026-04745-4#auth-Dongsheng-Yue-Aff1) [ORCID: orcid.org/0000-0002-5672-6164](https://orcid.org/0000-0002-5672-6164)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1) & * … * [Changli Wang](https://www.nature.com/articles/s41591-026-04745-4#auth-Changli-Wang-Aff1) [ORCID: orcid.org/0000-0003-1075-5071](https://orcid.org/0000-0003-1075-5071)[1](https://www.nature.com/articles/s41591-026-04745-4#Aff1) Show authors [_Nature Medicine_](https://www.nature.com/nm) (2026) [Cite this article](https://www.nature.com/articles/s41591-026-04745-4#citeas) Save article [ View saved research ](https://www.nature.com/saved-research) ## Abstract Resectable non-small cell lung cancer (NSCLC) carries a high risk of postoperative recurrence, underscoring the need for effective perioperative therapies. This nonrandomized, noncomparative phase 2 trial evaluated neoadjuvant ivonescimab monotherapy (cohort 1) or in combination with chemotherapy (cohort 2), followed by surgery and adjuvant ivonescimab. In cohort 2, the major pathological response (MPR) rate was 70.1% (47/67; 95% confidence interval (CI) = 57.7–80.7); the lower bound of the 80% two-sided CI exceeded the historical control rate of 41% and the primary endpoint was met. The MPR rate in cohort 1 was 60.0% (6/10; 95% CI = 26.2–87.8). Among patients who achieved MPR, 83.3% (5/6) in cohort 1 and 97.9% (46/47) in cohort 2 had residual viable tumor (RVT) of ≤5%, respectively. Grade 3 or higher treatment-related adverse events (AEs) occurred in 36.4% (4/11) patients in cohort 1 and 30.4% (24/79) of those in cohort 2, with no grade 3 or higher hemorrhage or treatment-related death. Treatment-related surgery delay occurred in one (1.3%) patient. Surgery-related AEs related to ivonescimab occurred in 10.0% (1/10) and 10.4% (7/67) patients in the two cohorts, respectively, with no grade 3 or higher events reported. These data support perioperative ivonescimab with or without chemotherapy as a promising strategy for resectable NSCLC. ClinicalTrials.gov identifier: [NCT05247684](https://clinicaltrials.gov/study/NCT05247684?term=NCT05247684&viewType=Table&rank=1). ### Explore related subjects Discover the latest articles and news in related subjects. * [Cancer immunotherapy](https://www.nature.com/subjects/cancer-immunotherapy) * [Phase II trials](https://www.nature.com/subjects/phase-ii-trials) * [Lung Cancer Diagnosis and Treatment Modalities](https://www.nature.com/subjects/lung-cancer-diagnosis-and-treatment-modalities) ## Main Non-small cell lung cancer (NSCLC) is the predominant pathological subtype of lung cancer, with approximately one-fourth of patients presenting with surgically resectable disease[1](https://www.nature.com/articles/s41591-026-04745-4#ref-CR1 "Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E. & Adjei, A. A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584–594 https://doi.org/10.4065/83.5.584 \(2008\)."),[2](https://www.nature.com/articles/s41591-026-04745-4#ref-CR2 "Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386, 1973–1985 https://doi.org/10.1056/nejmoa2202170 \(2022\)."). While surgery remains the primary curative treatment for early-stage NSCLC, patients (30–70%) develop postoperative recurrence[3](https://www.nature.com/articles/s41591-026-04745-4#ref-CR3 "Pignon, J. P. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26, 3552–3559 https://doi.org/10.1200/JCO.2007.13.9030 \(2008\)."), which often progresses to distant metastases and confers poor survival outcomes[4](https://www.nature.com/articles/s41591-026-04745-4#ref-CR4 "Boyd, J. A. et al. Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure. J. Thorac. Oncol. 5, 211–214 https://doi.org/10.1097/jto.0b013e3181c20080 \(2010\)."),[5](https://www.nature.com/articles/s41591-026-04745-4#ref-CR5 "Kelsey, C. R. et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer 115, 5218–5227 https://doi.org/10.1002/cncr.24625 \(2009\)."). Given the modest overall survival benefits of conventional neoadjuvant chemotherapy over surgery alone[6](https://www.nature.com/articles/s41591-026-04745-4#ref-CR6 "NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 383, 1561–1571 https://doi.org/10.1016/s0140-6736\(13\)62159-5 \(2014\)."), new neoadjuvant therapies are needed to improve pathological response and complete surgical resection rates, thereby reducing postoperative recurrence and prolonging survival. NSCLC is characterized by an immunosuppressive tumor microenvironment, in which cancer cells upregulate programmed cell death ligand 1 (PD-L1) expression to evade T-cell-mediated immune surveillance[7](https://www.nature.com/articles/s41591-026-04745-4#ref-CR7 "Cha, J. H., Chan, L. C., Li, C. W., Hsu, J. L. & Hung, M. C. Mechanisms controlling PD-L1 expression in cancer. Mol. Cell 76, 359–370 https://doi.org/10.1016/j.molcel.2019.09.030 \(2019\)."). In patients with resectable NSCLC, perioperative programmed cell death protein 1 (PD-1) or PD-L1 inhibitors have been shown to improve antitumor efficacy when combined with chemotherapy, as compared with standard chemotherapy alone. The first phase 3 trial on neoadjuvant immunochemotherapy, CheckMate 816, showed that neoadjuvant nivolumab in combination with chemotherapy significantly improved pathological complete response (pCR; 24% versus 2.2%) in patients with resectable NSCLC compared with chemotherapy alone[2](https://www.nature.com/articles/s41591-026-04745-4#ref-CR2 "Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386, 1973–1985 https://doi.org/10.1056/nejmoa2202170 \(2022\)."). Several subsequent phase 3 trials, including KEYNOTE-671, AEGEAN, Neotorch, CheckMate 77T and RATIONALE-315, also demonstrated superior pathological response with neoadjuvant immunochemotherapy, with major pathological response (MPR) rates ranging from 30.2% to 56% and pCR rates ranging from 17.2% to 41%[8](https://www.nature.com/articles/s41591-026-04745-4#ref-CR8 "Wakelee, H. et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N. Engl. J. Med. 389, 491–503 https://doi.org/10.1056/nejmoa2302983 \(2023\)."),[9](https://www.nature.com/articles/s41591-026-04745-4#ref-CR9 "Spicer, J. D. et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer \(KEYNOTE-671\): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 404, 1240–1252 https://doi.org/10.1016/s0140-6736\(24\)01756-2 \(2024\)."),[10](https://www.nature.com/articles/s41591-026-04745-4#ref-CR10 "Wakelee, H. et al. Five-year outcomes of perioperative pembrolizumab for early-stage non-small-cell lung cancer from the randomized KEYNOTE-671 study. Ann. Oncol. https://doi.org/10.1016/j.annonc.2026.08.005 \(2026\)."),[11](https://www.nature.com/articles/s41591-026-04745-4#ref-CR11 "Heymach, J. V. et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N. Engl. J. Med. 389, 1672–1684 https://doi.org/10.1056/nejmoa2304875 \(2023\)."),[12](https://www.nature.com/articles/s41591-026-04745-4#ref-CR12 "Lu, S. et al. Perioperative Toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the Neotorch randomized clinical trial. JAMA 331, 201–211 https://doi.org/10.1001/jama.2023.24735 \(2024\)."),[13](https://www.nature.com/articles/s41591-026-04745-4#ref-CR13 "Cascone, T. et al. Perioperative nivolumab in resectable lung cancer. N. Engl. J. Med. 390, 1756–1769 https://doi.org/10.1056/nejmoa2311926 \(2024\)."),[14](https://www.nature.com/articles/s41591-026-04745-4#ref-CR14 "Yue, D. et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer \(RATIONALE-315\): an interim analysis of a randomised clinical trial. Lancet Respir. Med. 13, 119–129 https://doi.org/10.1016/s2213-2600\(24\)00269-8 \(2025\)."). CheckMate 816, along with the subsequent phase 3 trials in which the same immunotherapy was administered in both the neoadjuvant and adjuvant phases, also demonstrated significant event-free survival (EFS) and overall survival benefit over standard chemotherapy[2](https://www.nature.com/articles/s41591-026-04745-4#ref-CR2 "Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386, 1973–1985 https://doi.org/10.1056/nejmoa2202170 \(2022\)."),[8](https://www.nature.com/articles
## Related Clinical Research

- [PD-L1 expression and survival in unresectable or recurrent gastric cancer treated with first-line](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-pd-l1-expression-and-survival-in-unresectable-recurrent-gastric-cancer-treated.md)
- [Immune checkpoint inhibitor–induced diabetes in metastatic NSCLC: case report, management, and fol](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-immune-checkpoint-inhibitor-induced-diabetes-mellitus-in-metastatic-nsclc-a.md)
- [Editorial placeholder: Innovative therapeutic approaches for complex cancers — source content miss](https://medichelpline.com/clinical-feed/frontiers-in-immunology-12-editorial-innovative-therapeutic-approaches-for-complex-cancers-exploring-new.md)
- [Enfortumab vedotin shows increased activity in cisplatin‑resistant HT1376 bladder cancer model](https://medichelpline.com/clinical-feed/plos-one-20-enhanced-enfortumab-vedotin-sensitivity-in-a-cisplatin-resistant-bladder-cancer.md)
- [Neoadjuvant nivolumab plus visugromab in MIBC: phase 2a GDFATHER-NEO findings](https://medichelpline.com/clinical-feed/nature-0-neoadjuvant-nivolumab-with-or-without-visugromab-in-muscle-invasive-bladder.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.